DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
Shinichi Yamashita, Masao Chujo, Toshihiko Moroga et al. · PubMed · 2009
BACKGROUND: The possibility of a dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase gene, DYRK2, predicting benefit from chemotherapy for patients with recurrent non-small cell lung cancer (NSCLC) was investigated. MATERIALS AND METHODS: Forty patients with recurrent disease after surgery received several combinations of platinum-based chemotherapy. The chemotherapy effectiveness was evaluated according to RECIST (response evaluation criteria in solid tumors). Immunohistochemical (IHC) analysis was used to determine the expression of DYRK2. RESULTS: Although the response rates between the two groups did not show statistical differences, the disease control rate of the DYRK2-positive group (15 out of 17, 88%) was significantly different from the DYRK2-negative group (8 out of 23, 35%, p=0.001). The median time to the progression (TTP) of disease was significantly different between the two groups (310 days in the positive group, 120 days in the negative, HR=2.12, 95% CI=[1.1-4.09], p=0.024). Multivariate analysis showed that negative DYRK2 expression was a strong predictor of disease progression (HR=3.01, 95% CI=[1.45-6.26], p=0.003). CONCLUSION: Patients with high DYRK2 expression could be good candidates for chemotherapy.
Cited by 33 works.
Authors
- Shinichi Yamashita
- Masao Chujo
- Toshihiko Moroga
- Kentaro Anami
- Keita Tokuishi
- Michiyo Miyawaki
- Yozo Kawano
- Shinsuke Takeno
- Satoshi Yamamoto
- Katsunobu Kawahara
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
- Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
- Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer
- Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non–Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy
- DYRK2 Is Targeted to the Nucleus and Controls p53 via Ser46 Phosphorylation in the Apoptotic Response to DNA Damage
- Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first‐line, systemic chemotherapy
- Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.